Alison R Moliterno Selected Research

Thrombocytosis (Thrombocythemia)

1/2021	The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.
1/2020	Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.
12/2014	Back to biology: new insights on inheritance in myeloproliferative disorders.
12/2014	Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
3/2013	MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients.
10/2011	Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.
8/2004	Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alison R Moliterno Research Topics

Disease

8	Neoplasms (Cancer) 01/2022 - 11/2011
7	Thrombocytosis (Thrombocythemia) 01/2021 - 08/2004
7	Polycythemia Vera 01/2021 - 10/2011
4	Thrombotic Thrombocytopenic Purpura 12/2021 - 06/2015
4	Thrombosis (Thrombus) 01/2016 - 11/2011
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 10/2011
3	Primary Myelofibrosis (Myelosclerosis) 01/2021 - 10/2011
3	Atypical Hemolytic Uremic Syndrome 01/2021 - 06/2015
3	Polycythemia (Erythrocytosis) 12/2014 - 10/2011
2	Inflammation (Inflammations) 01/2022 - 11/2011
2	Hypertension (High Blood Pressure) 12/2021 - 01/2019
2	Myocardial Infarction 12/2021 - 07/2019
2	Stroke (Strokes) 12/2021 - 01/2019
2	Hemorrhage 07/2019 - 06/2005
2	Hemolysis 01/2016 - 03/2008
2	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2016 - 06/2015
2	Hypersplenism (Anemia, Splenic) 10/2013 - 03/2008
2	Essential Thrombocythemia 03/2013 - 06/2005
2	Leukemia 11/2011 - 10/2011
2	Anemia 11/2011 - 10/2011
1	Acute Erythroblastic Leukemia (Erythroleukemia) 01/2022
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022
1	Obesity 12/2021
1	Atrial Fibrillation 12/2021
1	Autoimmune Diseases (Autoimmune Disease) 12/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2021
1	Diabetes Mellitus 12/2021
1	Hyperlipidemias (Hyperlipidemia) 12/2021
1	Chronic Renal Insufficiency 12/2021
1	COVID-19 10/2021
1	Acute Promyelocytic Leukemia 05/2021
1	Disease Progression 03/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Transfusion Reaction 01/2020
1	Persistent Infection 01/2020
1	Paraproteinemias (Monoclonal Gammopathy) 01/2020
1	Hemophilia A (Haemophilia) 07/2019
1	Heart Diseases (Heart Disease) 07/2019
1	Acute Coronary Syndrome 07/2019
1	Cognitive Dysfunction 01/2019
1	Genomic Instability 01/2018
1	Bone Marrow Failure Disorders 01/2016
1	Thrombotic Microangiopathies 06/2015
1	Leukocytosis (Pleocytosis) 12/2014
1	Splenomegaly 08/2014
1	Altitude Sickness (Mountain Sickness) 04/2013
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 03/2008
1	Sickle Cell Anemia (Hemoglobin S Disease) 11/2002
1	Sepsis (Septicemia) 11/2002
1	Respiratory Insufficiency (Respiratory Failure) 11/2002

Drug/Important Bio-Agent (IBA)

5	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2004
3	Thrombopoietin (c-mpl Ligand)IBA 10/2021 - 01/2020
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021 - 11/2015
3	Thrombopoietin ReceptorsIBA 01/2021 - 08/2004
3	thiamine triphosphorate (TTP)IBA 01/2020 - 06/2015
3	ruxolitinibIBA 01/2018 - 11/2011
3	Janus Kinase 2IBA 12/2014 - 08/2014
2	CytokinesIBA 01/2022 - 11/2011
2	fedratinibIBA 01/2022 - 11/2011
2	Complement System Proteins (Complement)IBA 01/2021 - 06/2015
2	Colony-Stimulating Factor Receptors (Colony-Stimulating Factor Receptor)IBA 01/2021 - 01/2020
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2018 - 12/2017
2	Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA 01/2016 - 06/2015
1	Chemokine ReceptorsIBA 01/2022
1	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2022
1	omega-Chloroacetophenone (Mace)IBA 12/2021
1	Biological ProductsIBA 03/2021
1	LigandsIBA 01/2021
1	AlbuminsIBA 01/2020
1	SolventsIBA 01/2020
1	Detergents (Detergent)IBA 01/2020
1	MetalsIBA 07/2019
1	emicizumabIBA 07/2019
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 07/2019
1	nutlin 3IBA 01/2018
1	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018
1	eculizumab FDA Link 01/2017
1	Hemoglobins (Hemoglobin)IBA 08/2014
1	OligonucleotidesIBA 08/2014
1	SiliconesIBA 10/2013
1	SaltsIBA 04/2013
1	MicroRNAs (MicroRNA)IBA 03/2013
1	Transcription Factors (Transcription Factor)IBA 11/2011
1	Janus Kinase InhibitorsIBA 11/2011
1	N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA 11/2011
1	DNA (Deoxyribonucleic Acid)IBA 10/2011
1	Nonsense Codon (Nonsense Mutation)IBA 10/2011
1	AutoantibodiesIBA 03/2008
1	Immunoglobulin G (IgG)IBA 03/2008
1	Messenger RNA (mRNA)IBA 06/2005
1	PolyHemeIBA 11/2002

Therapy/Procedure

11	Therapeutics 01/2022 - 11/2002
2	Drug Therapy (Chemotherapy) 08/2014 - 10/2011
1	Stents 07/2019
1	Percutaneous Coronary Intervention 07/2019
1	Splenectomy 08/2014
1	Breast Implants (Breast Implant) 10/2013
1	Pancreaticoduodenectomy 03/2008
1	Ligation 03/2008